Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey.
Laura D'ErasmoAntonio GalloAngelo Baldassare CefalùAlessia Di CostanzoSamir SahebAntonina GiammancoMaurizio AvernaAlessio BuonaiutoGabriella IannuzzoGiuliana FortunatoArturo PujaTiziana MontalciniChiara PavanelloLaura CalabresiGiovanni Battista VignaMarco BucciKatia BonomoFabio NotaTiziana SampietroFrancesco SbranaPatrizia SuppressaCarlo SabbàFabio FimianiArturo CesaroPaolo CalabròSilvia PalmisanoSergio D'AddatoLivia PisciottaStefano BertoliniRanda BittarOlga KalmykovaSophie BéliardAlain CarriéMarcello ArcaEric BruckertPublished in: Orphanet journal of rare diseases (2021)
In comparison with LA, lomitapide appears to provide a better control of LDL-C in HoFH. Further studies are needed to confirm this data and establish whether this translates into a reduction of cardiovascular risk.